The price cap would have lowered costs for Enbrel, an immunosuppressant drug made by Amgen.
Articles on Drug regulation
Displaying 1 - 20 of 30 articles
The psychiatrist used to have to stay with the patient during their entire session. Now they’ll be able to leave the room after administering the drug.
Legal recreational cannabis use comes with an increase in innovation – but tends to focus on what marketers and businesses are interested in, rather than health benefits and risks.
More people are accessing medicinal cannabis than ever expected, or the health system was designed for. And we’re failing patients.
Fifty years after its major drug law was introduced, NZ still lacks a clear picture of the harm drugs do. Asking drug users themselves offers surprising insights.
By extending their monopoly on a drug, companies prevent generics and other competitors from driving down prices. But increasing transparency can help prevent Big Pharma from gaming the patent system.
If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost down from around $500 a month to $31.60.
Aggressive and misleading marketing is fuelling demand for medicinal cannabis. Here are some of the ways clinics bend the rules.
Both Trump and Harris seek to lower drug costs for patients. What headway have they made on realizing this goal?
Regulating drugs may seem radical, but taking the production and sale of currently illegal drugs away from organized crime and drug cartels is the most promising way to keep our communities safe.
‘Natural’ isn’t the same thing as healthful. You can have too much of a good thing, and taking action can be worse than doing nothing.
An inhaler that costs nearly $300 in the US goes for just $9 in Germany. What gives?
Psychedelics are an opportunity to do better than our past drug control strategies. Adults should be trusted to make the right decisions, but policymakers should ensure they do so fully informed.
As the government’s oldest consumer protection agency, the FDA has long butted up against drugmakers, activists and politicians. But undermining its work could be harmful to patient health and safety.
India’s drug regulation is loose and results in dangerous medicines being sold at home and abroad.
Kava is not commonly used in Australia. But that will change and we need to keep an eye on what happens next.
Livelihoods which communities have relied on for centuries are being criminalised by heavy-handed state restrictions.
Australia is still aiming to start vaccinating high-risk groups from March. Why the delay?
Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
Opioid-related deaths in Australia have been on an upward trend in recent years, having doubled since 2006.
Top contributors
-
Professor of Bioethics, Macquarie University
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Assistant Professor of Resource Economics, UMass Amherst
-
Professor and Deputy Director, Monash Addiction Research Centre, Monash University
-
Associate Professor of History, University of Wollongong
-
Professor of Law and Public Health, The Ohio State University
-
Professor in Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, Northwestern University
-
Principal Enterprise Fellow, University of Huddersfield
-
Macquarie University Research Fellow, Macquarie University
-
Research Associate and PhD candidate, National Drug Research Institute, Curtin University
-
Professor, National Drug Research Institute, Curtin University and Burnet Institute, Burnet Institute
-
Lecturer, Clinical Psychologist, Edith Cowan University
-
Associate Lecturer, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Honorary Lecturer, School of Pharmacy, Charles Perkins Centre, University of Sydney
-
Assistant Director of Pharmacy, Mater Health SEQ in conjoint appointment as Associate Professor of Pharmacology, Bond University and as Associate Professor (Clinical), The University of Queensland